PDF herunterladen
Semin Reprod Med 2003; 21(3): 267-276
DOI: 10.1055/s-2003-43304
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diagnostic Criteria in Polycystic Ovary Syndrome

Richard S. Legro
  • Department of Obstetrics and Gynecology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Oktober 2003 (online)

    Lizenzen und Reprints

ABSTRACT

Part of the difficulty in understanding polycystic ovary syndrome (PCOS) and interpreting the dense literature surrounding it is that there is no universally accepted clinical definition. The varying definitions influence the incidence, prevalence of sequelae, and response to treatment. PCOS is clearly heterogeneous and its etiology is still speculative. Over the years it has evolved from a "disease" to a "syndrome," the latter which includes a variety of potential signs and symptoms, including oligo-ovulation, biochemical or clinical hyperandrogenism, polycystic ovaries, and insulin resistance. There is no single diagnostic criterion that can be recommended for diagnosis of PCOS. While hyperandrogenemia, specifically elevated bioavailable testosterone, is intellectually appealing, the evidence in terms of long-term sequelae identified by such a test is still weak. The recognition of oligo-ovulation primarily relies on patient history. Currently both consensus and the preliminary evidence-based trials support a combination of hyperandrogenemia and oligo-ovulation, in the absence of known causes, as diagnostic criteria, but there are also strong proponents of using ovarian morphology to identify and diagnose the syndrome. There are no simple clinically validated biochemical tests of insulin resistance. Further identification of specific causes, and elimination of the multiple phenocopies that make up PCOS, will ease its diagnosis.

KEYWORDS

Androgen excess - insulin resistance - ultrasonography - anovulation

REFERENCES

  • 1 Zawadski J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, ed. Polycystic Ovary Syndrome Boston: Blackwell Scientific 1992: 377-384
    Google Scholar
  • 2 Franks S. Polycystic ovary syndrome [published erratum appears in N Engl J Med 1995;333:1435].  N Engl J Med . 1995;  333 853-861
    CrossrefPubMedGoogle Scholar
  • 3 Lobo R A. A disorder without identity: "HCA," "PCO," "PCOD," "PCOS," "SLS". What are we to call it?.  [editorial]. Fertil Steril . 1995;  63 1158-1160
    PubMedGoogle Scholar
  • 4 Raj S G, Thompson I E, Berger M J, Talert L M, Taymor M L. Diagnostic value of androgen measurements in polycystic ovary syndrome.  Obstet Gynecol . 1978;  52 169-171
    PubMedGoogle Scholar
  • 5 Adams J, Polson D W, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.  Br Med J . 1986;  293 355-359
    CrossrefPubMedGoogle Scholar
  • 6 Legro R S, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1998;  83 2694-2698
    CrossrefPubMedGoogle Scholar
  • 7 Rebar R, Judd H L, Yen S S, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.  J Clin Invest . 1976;  57 1320-1329
    CrossrefPubMedGoogle Scholar
  • 8 Keettel W C, Bradbury J T, Stoddard F J. Observations on the PCO syndrome.  Am J Obstet Gynecol . 1957;  73 954-965
    PubMedGoogle Scholar
  • 9 McArthur J W, Ingersall F M, Worcester J. The urinary excretion of interstitial cell and follicle-stimulating hormone activity by women with diseases of the reproductive system.  J Clin Endocrinol Metab . 1958;  18 1202-1205
    PubMedGoogle Scholar
  • 10 Yen S S, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease.  J Clin Endocrinol Metab . 1970;  30 435-442
    CrossrefPubMedGoogle Scholar
  • 11 Robinson S, Rodin D A, Deacon A, Wheeler M J, Clayton R N. Which hormone tests for the diagnosis of polycystic ovary syndrome?.  Br J Obstet Gynaecol . 1992;  99 232-238
    PubMedGoogle Scholar
  • 12 Arroyo A, Laughlin G A, Morales A J, Yen S S. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.  J Clin Endocrinol Metab . 1997;  82 3728-3733
    CrossrefPubMedGoogle Scholar
  • 13 Taylor A E, McCourt B, Martin K A, Anderson E J, Adams J M, Schoenfeld D H. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1997;  82 2248-2256
    CrossrefPubMedGoogle Scholar
  • 14 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab . 1999;  84 165-169
    CrossrefPubMedGoogle Scholar
  • 15 Lobo R A, Shoupe D, Chang S P, Campeau J. The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome.  Am J Obstet Gynecol . 1984;  148 423-428
    PubMedGoogle Scholar
  • 16 Fauser B C, Pache T D, Hop W C, de Jong H F, Dahl K D. The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates.  Clin Endocrinol (Oxf) . 1992;  37 445-452
    PubMedGoogle Scholar
  • 17 Polson D W, Adams J, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women.  Lancet . 1988;  1 870-872
    PubMedGoogle Scholar
  • 18 Farquhar C M, Birdsall M, Manning P, Mitchell J M, France J T. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women.  Aust N Z J Obstet Gynaecol . 1994;  34 67-72
    PubMedGoogle Scholar
  • 19 Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H. The prevalence of polycystic ovaries in healthy women.  Acta Obstet Gynecol Scand . 1999;  78 137-141
    CrossrefPubMedGoogle Scholar
  • 20 Chang P L, Lindheim S R, Lowre C. et al . Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.  J Clin Endocrinol Metab . 2000;  85 995-1000
    CrossrefPubMedGoogle Scholar
  • 21 Carmina E, Wong L, Chang L. et al . Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.  Hum Reprod . 1997;  12 905-909
    CrossrefPubMedGoogle Scholar
  • 22 Loucks T L, Talbott E O, McHugh K P, Keelan M, Berga S L, Guzick D S. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?.  Fertil Steril . 2000;  74 547-552
    CrossrefPubMedGoogle Scholar
  • 23 Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.  Fertil Steril . 1999;  71 808-814
    CrossrefPubMedGoogle Scholar
  • 24 Koskinen P, Penttila T A, Anttila L, Erkkola R, Irjala K. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome.  Fertil Steril . 1996;  65 517-522
    PubMedGoogle Scholar
  • 25 Fox R, Corrigan E, Thomas P A, Hull M G. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests.  Clin Endocrinol (Oxf) . 1991;  34 127-131
    PubMedGoogle Scholar
  • 26 Legro R S, Driscoll D, Strauss III F J, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.  Proc Natl Acad Sci U S A . 1998;  95 14956-14960
    CrossrefPubMedGoogle Scholar
  • 27 Nestler J E. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? [editorial; comment].   J Clin Endocrinol Metab . 1993;  76 273-274
    PubMedGoogle Scholar
  • 28 Boots L R, Potter S, Potter D, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability.  Fertil Steril . 1998;  69 286-292
    CrossrefPubMedGoogle Scholar
  • 29 Ibanez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence.  J Clin Endocrinol Metab . 1999;  84 2691-2695
    CrossrefPubMedGoogle Scholar
  • 30 Winters S J, Talbott E, Guzick D S, Zborowski J, McHugh K P. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome.  Fertil Steril . 2000;  73 724-729
    CrossrefPubMedGoogle Scholar
  • 31 Moran C, Tapia M C, Hernandez E, Vazquez G, Garcia-Hernandez E. Etiological review of hirsutism in 250 patients.  Arch Med Res . 1994;  25 311-314
    PubMedGoogle Scholar
  • 32 Lobo R A, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome.  J Clin Endocrinol Metab . 1983;  57 393-397
    CrossrefPubMedGoogle Scholar
  • 33 Carmina E, Koyama T, Chang L, Stanczyk F Z, Lobo R A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?.  Am J Obstet Gynecol . 1992;  167 1807-1812
    PubMedGoogle Scholar
  • 34 Barth J H. How robust is the methodology for trials of therapy in hirsute women?.  Clin Endocrinol (Oxf) . 1996;  45 379-380
    CrossrefPubMedGoogle Scholar
  • 35 Holdaway I M, Fraser A, Sheehan A, Croxson M S, France J T, Ibbertson H K. Objective assessment of treatment response in hirsutism.  Horm Res . 1985;  22 253-259
    PubMedGoogle Scholar
  • 36 Hatch R, Rosenfield R L, Kim M H, Tredway D. Hirsutism: implications, etiology, and management.  Am J Obstet Gynecol . 1981;  140 815-830
    Google Scholar
  • 37 Lorenzo E M. Familial study of hirsutism.  J Clin Endocrinol Metab . 1970;  31 556-564
    PubMedGoogle Scholar
  • 38 Derksen J, Moolenaar A J, Van Seters P A, Kock D F. Semiquantitative assessment of hirsutism in Dutch women.  Br J Dermatol . 1993;  128 259-263
    PubMedGoogle Scholar
  • 39 Knochenhauer E S, Hines G, Conway-Myers B A, Azziz R. Examination of the chin or lower abdomen only for the prediction of hirsutism.  Fertil Steril . 2000;  74 980-983
    CrossrefPubMedGoogle Scholar
  • 40 Azziz R, Ehrmann D, Legro R S. et al . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.  J Clin Endocrinol Metab . 2001;  86 1626-1632
    CrossrefPubMedGoogle Scholar
  • 41 Azziz R, Waggoner W T, Ochoa T, Knochenhauer E S, Boots L R. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama.  Fertil Steril . 1998;  70 274-278
    CrossrefPubMedGoogle Scholar
  • 42 Elting M W, Korsen T J, Rekers-Mombarg L T, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing.  Hum Reprod . 2000;  15 24-28
    CrossrefPubMedGoogle Scholar
  • 43 Barbieri R L, Ryan K J. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features.  Am J Obstet Gynecol . 1983;  147 90-101
    PubMedGoogle Scholar
  • 44 American Diabetic Association. Consensus Development Conference on Insulin Resistance: 5-6 November 1997.  Diabetes Care . 1998;  21 310-314
    PubMedGoogle Scholar
  • 45 DeFronzo R A, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.  Diabetes Care . 1991;  14 173-194
    CrossrefPubMedGoogle Scholar
  • 46 Ehrmann D A, Sturis J, Byrne M M, Karrison T, Rosenfield R L, Polonsky K S. Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.  J Clin Invest . 1995;  96 520-527
    CrossrefPubMedGoogle Scholar
  • 47 Dunaif A, Finegood D T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.  J Clin Endocrinol Metab . 1996;  81 942-947
    CrossrefPubMedGoogle Scholar
  • 48 Pimenta W, Korytkowski M, Mitrakou A. et al . Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.  JAMA . 1995;  273 1855-1861
    CrossrefPubMedGoogle Scholar
  • 49 Harris M I, Hadden W C, Knowler W C, Bennett P H. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr.  Diabetes . 1987;  36 523-534
    CrossrefPubMedGoogle Scholar
  • 50 Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.  Diabetes Care . 1999;  22 141-146
    CrossrefPubMedGoogle Scholar
  • 51 Falsetti L, Eleftheriou G. Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine, and echographic study in 240 patients.  Gynecol Endocrinol . 1996;  10 319-326
    PubMedGoogle Scholar
  • 52 Golland I M, Vaughan Williams A C, Shalet S M, Million L H, Elstein M. Lack of predictive value of HbA1 for impaired glucose tolerance in polycystic ovary syndrome.  Gynecol Endocrinol . 1989;  3 229-235
    CrossrefPubMedGoogle Scholar
  • 53 Harris M I, Eastman R C, Cowie C C, Flegal K M, Eberhardt M S. Comparison of diabetes diagnostic categories in the US population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria.  Diabetes Care . 1997;  20 1859-1862
    CrossrefPubMedGoogle Scholar
  • 54 DeFronzo R A, Tobin J D, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance.  Am J Physiol . 1979;  237 E214-E223
    PubMedGoogle Scholar
  • 55 Bergman R N, Prager R, Volund A, Olefsky J M. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.  J Clin Invest . 1987;  79 790-800
    PubMedGoogle Scholar
  • 56 Norman R J, Masters S C, Hague W, Beng C, Pannall P, Wang J X. Metabolic approaches to the subclassification of polycystic ovary syndrome.  Fertil Steril . 1995;  63 329-335
    PubMedGoogle Scholar
  • 57 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab . 1998;  83 3078-3082
    CrossrefPubMedGoogle Scholar
  • 58 Diamanti-Kandarakis E, Kouli C R, Bergiele A T. et al . A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.  J Clin Endocrinol Metab . 1999;  84 4006-4011
    CrossrefPubMedGoogle Scholar
  • 59 Asuncion M, Calvo R M, San Millan L J, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.  J Clin Endocrinol Metab . 2000;  85 2434-2438
    CrossrefPubMedGoogle Scholar
  • 60 Talbott E, Guzick D, Clerici A. et al . Coronary heart disease risk factors in women with polycystic ovary syndrome.  Arterioscler Thromb Vasc Biol . 1995;  15 821-826
    CrossrefPubMedGoogle Scholar
  • 61 Talbott E O, Guzick D S, Sutton-Tyrrell K. et al . Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.  Arterioscler Thromb Vasc Biol . 2000;  20 2414-2421
    PubMedGoogle Scholar
  • 62 Legro R S, Kunselman A R, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.  Am J Med . 2001;  111 607-613
    CrossrefPubMedGoogle Scholar
  • 63 Nestler J E, Jakubowicz D J. Decreases in ovarian cytochrome P450C17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.  N Engl J Med . 1996;  335 617-623
    CrossrefPubMedGoogle Scholar
  • 64 Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.  N Engl J Med . 1999;  340 1314-1320
    CrossrefPubMedGoogle Scholar
  • 65 Urbanek M, Legro R S, Driscoll D A. et al . Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin.  Proc Natl Acad Sci U S A . 1999;  96 8573-8578
    CrossrefPubMedGoogle Scholar
  • 66 Kahsar-Miller M D, Nixon C, Boots L R, Go R C, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.  Fertil Steril . 2001;  75 53-58
    CrossrefPubMedGoogle Scholar